Form 4: CalciMedica Executive Granted Significant Stock Options Following Shareholder Approval

CalciMedica, Inc. Chief Business Officer Eric W. Roberts was granted 72,750 employee stock options with an exercise price of $1.53, following shareholder approval of the company's amended equity incentive plan.

Summary

• Eric W. Roberts, who serves as Chief Business Officer, Director, and 10% Owner of CalciMedica, Inc. (CALC), was granted 72,750 employee stock options.
• The granted options have an exercise price of $1.53 per share.
• The option grant was initially approved by CalciMedica's Board of Directors on April 23, 2025, contingent upon stockholder approval of an amendment to the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP").
• Stockholders subsequently approved the Amended 2023 EIP on June 24, 2025, making the option grant effective on that date.
• The options are immediately exercisable and are set to expire on April 22, 2035.
• Following this transaction, Eric W. Roberts directly beneficially owns 72,750 derivative securities (employee stock options).

Sentiment

Score: 7

Explanation: The sentiment is positive as the grant of stock options to a key executive aligns management's long-term interests with those of shareholders, which is a standard and generally favorable practice in corporate governance and executive compensation.

Positives

• The grant of stock options to a key executive like Eric W. Roberts aligns management's long-term interests directly with those of shareholders, incentivizing value creation.
• Shareholder approval of the Amended 2023 Equity Incentive Plan demonstrates support for the company's long-term compensation strategy and ability to attract and retain talent.
• The immediate exercisability of the options provides flexibility to the executive.

Future Outlook

The grant of long-term employee stock options to a key executive suggests an expectation of future value creation and aligns the executive's incentives with the company's long-term performance, though no explicit forward-looking statements or guidance are provided in this specific filing.

Industry Context

This Form 4 filing details a standard executive compensation event within the biotechnology or pharmaceutical industry, where equity incentives are a common tool for attracting, retaining, and motivating key personnel. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• The granting of stock options to executives is a widely accepted practice in the biotechnology and pharmaceutical sectors, aligning executive interests with shareholder value creation.
• The specific terms, such as the exercise price and number of options, would typically be benchmarked against peer companies of similar size, stage of development, and market capitalization, though no specific comparable companies or projects are mentioned in this filing.

Corporate Governance

Related Party Transactions

• Grant of 72,750 employee stock options to Eric W. Roberts, who is a Director, 10% Owner, and Chief Business Officer of CalciMedica, Inc., with an exercise price of $1.53 per share, under the Amended 2023 Equity Incentive Plan.

Stakeholder Impact

• Shareholders: The grant of options to a key executive aims to align management's incentives with shareholder interests, potentially leading to long-term value creation.
• Employees: The approval of the Amended 2023 Equity Incentive Plan suggests a broader framework for equity incentives, which could benefit other employees by providing opportunities for long-term compensation and ownership.

Key Dates

Keywords

CalciMedica, CALC, Stock Option, Equity Incentive Plan, Executive Compensation, Form 4, Insider Transaction, Eric W. Roberts, Chief Business Officer, Derivative Securities